Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [619]
News [1052]
Articles [54]
Editorials [2]
Conferences [97]
elearning [5]
Addition of S-1 to post-operative endocrine therapy for patients with hormone...
Prof Masakazu Toi - Kyoto University, Kyoto, Japan
Addition of S-1 to post-operative endocrine therapy for patients with hormone receptor-positive HER2-negative breast cancer ( Prof Masakazu Toi - Kyoto University, Kyoto, Japan )
18 Dec 2019
Laser therapy for vulvo-vaginal atrophy / genito-urinary syndrome of menopause...
Prof Deborah Fenlon - Swansea University, Swansea, UK
Laser therapy for vulvo-vaginal atrophy / genito-urinary syndrome of menopause in breast cancer survivors ( Prof Deborah Fenlon - Swansea University, Swansea, UK )
12 Dec 2019
PROfound: PARP inhibitor olaparib compared with new hormonal agents in advanced...
Prof Maha Hussain - Northwestern University Feinberg School of Medicine...
PROfound: PARP inhibitor olaparib compared with new hormonal agents in advanced castration resistant prostate cancer ( Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago, USA )
7 Nov 2019
Highlights from ESMO 2019
Prof Josep Tabernero - ESMO President
Highlights from ESMO 2019 ( Prof Josep Tabernero - ESMO President )
4 Oct 2019
Prostate cancer updates: Advances in precision medicine and PARP inhibitors
Prof Karim Fizazi, Dr Joaquin Mateo, Dr Shahneen Sandhu and Prof Bertrand Tombal
Prostate cancer updates: Advances in precision medicine and PARP inhibitors ( Prof Karim Fizazi, Dr Joaquin Mateo, Dr Shahneen Sandhu and Prof Bertrand Tombal )
2 Oct 2019
Breast cancer highlights from ESMO 2019
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
Breast cancer highlights from ESMO 2019 ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
2 Oct 2019
Melanoma highlights from ESMO 2019
Dr Teresa Amaral - University Hospital Tübingen, Tübingen, Germany
Melanoma highlights from ESMO 2019 ( Dr Teresa Amaral - University Hospital Tübingen, Tübingen, Germany )
30 Sep 2019
PARP inhibitor olaparib slows progression of advanced prostate cancer
Prof Maha Hussain - Northwestern University Feinberg School of Medicine...
PARP inhibitor olaparib slows progression of advanced prostate cancer ( Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago, USA )
30 Sep 2019
Comment: PARP inhibitors for advanced prostate cancer
Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain
Comment: PARP inhibitors for advanced prostate cancer ( Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain )
30 Sep 2019
Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019
Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith
Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019 ( Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith )
30 Sep 2019
MONALEESA-3: Ribociclib plus fulvestrant in advanced breast cancer
Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, USA
MONALEESA-3: Ribociclib plus fulvestrant in advanced breast cancer ( Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, USA )
29 Sep 2019
Improvement in OS with abemaciclib plus fulvestrant in pre-, peri- and...
Prof George Sledge - Stanford Health Care, Stanford, USA
Improvement in OS with abemaciclib plus fulvestrant in pre-, peri- and postmenopausal HR-positive, HER2-negative advanced breast cancer resistant to hormonal therapy ( Prof George Sledge - Stanford Health Care, Stanford, USA )
29 Sep 2019

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation